CENTESSA-Icon-Logo

Mary Lynne Hedley PhD

Senior Fellow and Strategic Advisor

The Broad Institute of M.I.T. and Harvard

Dr. Mary Lynne Hedley, PhD, is a Senior Fellow and Strategic Advisor at The Broad Institute of M.I.T. and Harvard and Co-Founder, former President, Director and Chief Operating Officer at TESARO, Inc.

Mary Lynne has extensive experience in the discovery and development of new medicines, formerly serving as Executive Vice President and Chief Scientific Officer at MGI PHARMA, Executive Vice President of Eisai Corporation of North America, Executive Vice President of Operations, and Chief Scientific Officer of Abraxis BioScience.

Mary Lynne also sits on the Veeva Systems (NASDAQ: VEEV) Board of Directors and is a member of the Helsinn Holdings’ Board of Directors.

Mary Lynne holds a PhD in Immunology from the University of Texas Southwestern Medical Center and a BS in Microbiology from Purdue University. In addition, she completed two consecutive postdoctoral fellowships at Harvard University.

Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B